Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Lancet Haematol. 2018 Dec;5(12):e609–e617. doi: 10.1016/S2352-3026(18)30177-7

Figure 2.

Figure 2.

Kaplan–Meier Estimates of event-free (EFS) and overall survival (OS) of MYC-R lymphoma. A. EFS of 53 patients with MYC-R lymphoma at 48-months was 71% (95% confidence interval [CI], 56.5–81.4%). B. OS of 53 patients with MYC-R lymphoma at 48-months was 76.7 (95% CI: 62.6–86.1%). C. EFS of single-hit (n=19) versus double-hit (n=24) lymphoma at 48-months was 62.7% (95% CI: 37.2–80.2%) and 73.4% (95% CI: 50.1–87.1%), respectively. D. OS of single-hit (n=19) versus double-hit (n=24) lymphoma at 48-months was 63.2% (95% CI: 38–80.4%) and 82% (95% CI: 58.892.8%), respectively. E. EFS of MYC-R lymphoma by negative (n=17) verus positive (n=31) interim FDG-PET at 48-months was 87.4% (95% CI: 58.1–96.7%) and 64.5% (95% CI: 45.2–78.5%), respectively. F. OS of MYC-R lymphoma by negative (n=17) verus positive (n=31) interim FDG-PET at 48-months was 87.5% (95% CI: 58.6–96.7%) and 74.2% (95% CI: 55–86.2%), respectively.